Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.45 |
| ▸ | RAB9A | P51151 | 6/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1228956 | 0.84 | MAPT (0.50) | HTTRECQLALDH1A1RAB9APOLB | |
| SCHEMBL21917164 | 0.84 | HTT (0.56) | HTTRECQLALDH1A1RAB9APOLB | |
| SCHEMBL2440881 | 0.84 | HTT (0.49) | HTTRECQLALDH1A1RAB9APOLB | |
| SCHEMBL5941039 | 0.81 | HTT (0.49) | HTTRECQLALDH1A1RAB9APOLB | |
| SCHEMBL5941099 | 0.81 | HTT (0.64) | HTTRECQLALDH1A1RAB9APOLB | |
| SCHEMBL2439673 | 0.81 | HTT (0.49) | HTTRECQLALDH1A1RAB9APOLB | |
| SCHEMBL3527060 | 0.81 | HTT (0.68) | HTTRECQLALDH1A1RAB9APOLB | |
| SCHEMBL2436285 | 0.81 | HTT (0.49) | HTTRECQLALDH1A1RAB9APOLB | |
| SCHEMBL5941017 | 0.80 | HTT (0.48) | HTTRECQLALDH1A1RAB9APOLB | |
| SCHEMBL13546620 | 0.79 | HTT (0.50) | HTTRECQLALDH1A1RAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220072019-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NAD+ OR A NAD+ PRECURSOR | DISARM THERAPEUTICS, INC. | 2022-03-10 | — | — | US | disclosed |
| US-20220008405-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NEURO-PROTECTIVE AGENTS | DISARM THERAPEUTICS, INC. | 2022-01-13 | — | — | US | disclosed |
| WO-2020132045-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NEUROPROTECTIVE AGENTS | DISARM THERAPEUTICS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020081923-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NAD+ OR A NAD+ PRECURSOR | DISARM THERAPEUTICS, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| US-6989451-B2 | Substituted isothiazole compounds are useful for treating the diseases associated with abnormality in protein kinases(especially MAP kinases) | VALEANT RESEARCH & DEVELOPMENT (US) | 2006-01-24 | — | — | US | disclosed |
| US-20040039037-A1 | Heterocyclic compounds and uses thereof | VALEANT PHARMA POLAND SPOLKA Z ORGANICZONA ODPOWIEDZIALNOSCIA (PL) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220072019-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NAD+ OR A NAD+ PRECURSOR | SARM1, NNMT, NQO1 | HTT 155/4885RECQL 1696/4885ALDH1A1 1724/4885 |
| US-20040039037-A1 | Heterocyclic compounds and uses thereof | MAP3K1, MAP3K20, MAP4K2 | HTT 2684/4885RECQL 3054/4885ALDH1A1 2646/4885 |
| US-20220008405-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NEURO-PROTECTIVE AGENTS | SARM1, SMN1; SMN2, SARNP | HTT 53/4885RECQL 2458/4885ALDH1A1 3928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.